Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""lenalidomide"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 41-60 z 6880
Tytuł:
Plasma Cell Leukemia with Successful Upfront Venetoclax in Combination with Allogeneic Transplantation.
Autorzy:
Tang ASO; Hematology Department, Ampang Hospital, Ampang, Ministry of Health, Malaysia.
Ahmad Asnawi AW; Hematology Department, Ampang Hospital, Ampang, Ministry of Health, Malaysia.; Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Negeri Sembilan, Ministry of Health, Malaysia.
Koh AZY; Hematology Department, Ampang Hospital, Ampang, Ministry of Health, Malaysia.
Chong SL; Hematology Department, Ampang Hospital, Ampang, Ministry of Health, Malaysia.
Liew PK; Hematology Department, Ampang Hospital, Ampang, Ministry of Health, Malaysia.
Selvaratnam V; Hematology Department, Ampang Hospital, Ampang, Ministry of Health, Malaysia.
Md Fauzi A; Hematology Department, Ampang Hospital, Ampang, Ministry of Health, Malaysia.; Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Negeri Sembilan, Ministry of Health, Malaysia.
Lau NS; Hematology Department, Ampang Hospital, Ampang, Ministry of Health, Malaysia.
Tan SM; Hematology Department, Ampang Hospital, Ampang, Ministry of Health, Malaysia.
Pokaż więcej
Źródło:
The American journal of case reports [Am J Case Rep] 2023 Mar 08; Vol. 24, pp. e938868. Date of Electronic Publication: 2023 Mar 08.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Leukemia, Plasma Cell*/diagnosis
Leukemia, Plasma Cell*/therapy
Female ; Humans ; Bortezomib ; Lenalidomide ; Transplantation, Homologous ; Dexamethasone
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma.
Autorzy:
Tang W; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Li Y; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zou Z; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.; Department of Hematology, Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, China.
Cui J; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Wang F; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zheng Y; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Hou L; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Pan L; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xiang B; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Chang H; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhang L; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Niu T; Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Feb; Vol. 12 (3), pp. 3054-3067. Date of Electronic Publication: 2022 Sep 20.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
B-Lymphocytes, Regulatory*
Multiple Myeloma*/drug therapy
Aged ; Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib ; Dexamethasone ; Disease-Free Survival ; Lenalidomide ; Positron Emission Tomography Computed Tomography ; Prospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma.
Autorzy:
Bici A; Department of Pharmacy Services, Michigan Medicine and the University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Pianko MJ; Division of Hematology and Oncology, Department of Internal Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Nachar VR; Department of Pharmacy Services, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Feb; Vol. 64 (2), pp. 407-414. Date of Electronic Publication: 2022 Oct 29.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Multiple Myeloma*/epidemiology
Bacterial Infections*/diagnosis
Bacterial Infections*/epidemiology
Bacterial Infections*/etiology
Humans ; Infant ; Lenalidomide/adverse effects ; Bortezomib/adverse effects ; Incidence ; Retrospective Studies ; Cohort Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Risk Factors ; Dexamethasone/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Autorzy:
Susek KH; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Gran C; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Department of Clinical Chemistry, Karolinska University Laboratory, Stockholm, Sweden.
Ljunggren HG; Center for Infectious Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Alici E; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Nahi H; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2020 Dec; Vol. 105 (6), pp. 751-754. Date of Electronic Publication: 2020 Aug 18.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal/*adverse effects
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Coronavirus Infections/*diagnosis
Dexamethasone/*adverse effects
Lenalidomide/*adverse effects
Multiple Myeloma/*diagnosis
Pneumonia, Viral/*diagnosis
Thalidomide/*adverse effects
Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Betacoronavirus/pathogenicity ; COVID-19 ; Cohort Studies ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Dexamethasone/administration & dosage ; Disease Progression ; Female ; Humans ; Immunomodulation ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/immunology ; Multiple Myeloma/mortality ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Prognosis ; Remission Induction ; SARS-CoV-2 ; Severity of Illness Index ; Survival Analysis ; Thalidomide/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
Autorzy:
Yau P; Department of Pharmacy, Tom Baker Cancer Center, Calgary, AB, Canada.
Jimenez-Zepeda VH; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
Bailey K; Department of Pharmacy, Tom Baker Cancer Center, Calgary, AB, Canada.
Duggan P; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
Tay J; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
Bahlis NJ; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
Neri P; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
McCulloch S; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (13), pp. 3199-3203. Date of Electronic Publication: 2019 Jun 13.
Typ publikacji:
Journal Article
MeSH Terms:
Desensitization, Immunologic/*methods
Drug Eruptions/*therapy
Exanthema/*therapy
Hypersensitivity, Delayed/*therapy
Immunologic Factors/*administration & dosage
Lenalidomide/*administration & dosage
Multiple Myeloma/*drug therapy
Aged ; Aged, 80 and over ; Cancer Care Facilities ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Eruptions/etiology ; Exanthema/chemically induced ; Exanthema/immunology ; Female ; Humans ; Hypersensitivity, Delayed/chemically induced ; Hypersensitivity, Delayed/immunology ; Immunologic Factors/adverse effects ; Immunologic Factors/immunology ; Lenalidomide/adverse effects ; Lenalidomide/immunology ; Male ; Middle Aged ; Multiple Myeloma/immunology ; Outpatient Clinics, Hospital ; Skin/drug effects ; Skin/immunology ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.
Autorzy:
Kuruvilla J; Princess Margaret Cancer Centre, Toronto, Canada.
Armand P; Dana-Farber Cancer Institute, Boston, MA, USA.
Hamadani M; Medical College of Wisconsin, Milwaukee, WI, USA.
Kline J; Department of Medicine, University of Chicago, Chicago, IL, USA.
Moskowitz CH; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Avigan D; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Brody JD; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ribrag V; Gustave Roussy, Villejuif, France.
Herrera AF; City of Hope, Duarte, CA, USA.
Morschhauser F; Department of Hematology, CHU Lille, Lille University, Lille, France.
Kanate A; HonorHealth Cancer Transplant Institute, Scottsdale, AZ, USA.
Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy.
Bitran J; Advocate Lutheran General Hospital, Park Ridge, IL, USA.
Ghesquieres H; Lyon-Sud Hospital Center, Lyon, France.
Schuster SJ; Department of Medicine, Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Farooqui M; Merck & Co., Inc., Rahway, NJ, USA.
Marinello P; Merck & Co., Inc., Rahway, NJ, USA.
Bartlett NL; Siteman Cancer Center, Washington University, St. Louis, MO, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Jan; Vol. 64 (1), pp. 130-139. Date of Electronic Publication: 2022 Nov 18.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal, Humanized*/adverse effects
Lymphoma, Non-Hodgkin*/diagnosis
Lymphoma, Non-Hodgkin*/drug therapy
Humans ; Lenalidomide/adverse effects ; Neoplasm Recurrence, Local
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.
Autorzy:
Dote S; Department of Pharmacy, Kyoto-Katsura Hospital, Kyoto, Japan.; Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan.
Ito K; Department of Pharmacy, Fujita Health University Hospital, Aichi, Japan.
Itakura S; Department of Pharmacy, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Yasu T; Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hira D; Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan.; College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
Noda S; Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan.
Yamada S; Department of Pharmacy, Fujita Health University Hospital, Aichi, Japan.
Kobayashi Y; Department of Pharmacy, Kyoto-Katsura Hospital, Kyoto, Japan.
Terada T; Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (12), pp. 2975-2981. Date of Electronic Publication: 2019 May 03.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Bortezomib/*adverse effects
Exanthema/*epidemiology
Exanthema/*etiology
Lenalidomide/*adverse effects
Multiple Myeloma/*complications
Multiple Myeloma/*epidemiology
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/therapeutic use ; Cohort Studies ; Disease Susceptibility ; Eosinophilia/diagnosis ; Eosinophilia/epidemiology ; Eosinophilia/etiology ; Exanthema/diagnosis ; Female ; Humans ; Incidence ; Lenalidomide/therapeutic use ; Male ; Multiple Myeloma/drug therapy ; Propensity Score
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Autorzy:
Sinit RB; Floyd and Delores Jones Cancer Institute, Virginia Mason Medical Center, 1100 Ninth Avenue (C2-HEM), Seattle, WA, 98101, USA.
Hwang DG; Department of Pathology, Virginia Mason Medical Center, Seattle, WA, USA.
Vishnu P; Department of Medical Oncology, Mayo Clinic, Jacksonville, FL, USA.
Peterson JF; Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Aboulafia DM; Floyd and Delores Jones Cancer Institute, Virginia Mason Medical Center, 1100 Ninth Avenue (C2-HEM), Seattle, WA, 98101, USA. .; Division of Hematology, University of Washington School of Medicine, Seattle, WA, USA. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Nov 27; Vol. 19 (1), pp. 1147. Date of Electronic Publication: 2019 Nov 27.
Typ publikacji:
Case Reports; Journal Article; Review
MeSH Terms:
Lenalidomide/*adverse effects
Multiple Myeloma/*diagnosis
Multiple Myeloma/*etiology
Neoplasms, Second Primary/*diagnosis
Neoplasms, Second Primary/*etiology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*etiology
Thalidomide/*adverse effects
Aged ; Aged, 80 and over ; Biomarkers, Tumor ; Bone Marrow ; Humans ; Immunologic Factors/adverse effects ; Immunologic Factors/therapeutic use ; Lenalidomide/therapeutic use ; Male ; Thalidomide/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
Autorzy:
Ataca Atilla P; Ankara University Faculty of Medicine, Department of Hematology, Ankara, Turkey
Yalçıner M; Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey
Atilla E; Ankara University Faculty of Medicine, Department of Hematology, Ankara, Turkey
İdilman R; Ankara University Faculty of Medicine, Department of Gastroenterology, Ankara, Turkey
Beksaç M; Ankara University Faculty of Medicine, Department of Hematology, Ankara, Turkey
Pokaż więcej
Źródło:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2019 Nov 18; Vol. 36 (4), pp. 266-273. Date of Electronic Publication: 2019 Aug 01.
Typ publikacji:
Journal Article
MeSH Terms:
Angiogenesis Inhibitors/*therapeutic use
Antineoplastic Agents/*therapeutic use
Bortezomib/*therapeutic use
Hepatitis B virus/*pathogenicity
Lenalidomide/*therapeutic use
Multiple Myeloma/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/pharmacology ; Antineoplastic Agents/pharmacology ; Bortezomib/pharmacology ; Female ; Humans ; Lenalidomide/pharmacology ; Male ; Middle Aged ; Retrospective Studies ; Virus Activation
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.
Autorzy:
Zeidan AM; a Department of Internal Medicine , Yale University , New Haven , CT , USA.
Klink AJ; b Cardinal Health Specialty Solutions , Dublin , OH , USA.
McGuire M; c Celgene Corporation , Summit , NJ , USA.
Feinberg B; b Cardinal Health Specialty Solutions , Dublin , OH , USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Aug; Vol. 60 (8), pp. 2050-2055. Date of Electronic Publication: 2019 Jan 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antimetabolites, Antineoplastic/*therapeutic use
Lenalidomide/*therapeutic use
Myelodysplastic Syndromes/*drug therapy
Myelodysplastic Syndromes/*mortality
Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Clinical Decision-Making ; Disease Management ; Female ; Humans ; Lenalidomide/administration & dosage ; Male ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/etiology ; Prognosis ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.
Autorzy:
Zhi Y; Department of Hematology, The People's Hospital of Tai Zhou, Nanjing Medical University, Nanjing, People's Republic of China.
Bao S; The People's Hospital of Zhang Dian, Jiangyan, People's Republic of China.
Mao J; Department of Hematology, The People's Hospital of Tai Zhou, Nanjing Medical University, Nanjing, People's Republic of China.
Chai G; Department of Hematology, The People's Hospital of Tai Zhou, Nanjing Medical University, Nanjing, People's Republic of China.
Zhu J; Department of Hematology, The People's Hospital of Tai Zhou, Nanjing Medical University, Nanjing, People's Republic of China.
Liu C; Department of General Practice, Anhui Medical University, Hefei, People's Republic of China.
Chen X; Department of Epidemiology and Statistics, School of Public Health, Medical College, Zhejiang University, Hangzhou, People's Republic of China.; School of Health, Brooks College, Sunnyvale, CA, USA.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 1069-1088.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Multiple Myeloma*/diagnosis
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Boron Compounds ; Bortezomib ; Glycine/analogs & derivatives ; Humans ; Lenalidomide/therapeutic use ; Network Meta-Analysis ; Prednisone/therapeutic use ; Thalidomide
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.
Autorzy:
Tsubokura Y; First Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan.
Yoshimura H; First Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan.
Satake A; First Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan.
Nasa Y; First Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan.
Tsuji R; First Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan.
Ito T; First Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan.
Nomura S; First Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan.
Pokaż więcej
Źródło:
Immunity, inflammation and disease [Immun Inflamm Dis] 2022 Sep; Vol. 10 (9), pp. e688.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Graft vs Host Disease*/prevention & control
Hematopoietic Stem Cell Transplantation*/adverse effects
Cell Movement ; Gastrointestinal Tract ; Humans ; Lenalidomide ; Transplantation, Homologous/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
Autorzy:
Lahoud OB; Adult Bone Marrow Transplant Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Landau H; Adult Bone Marrow Transplant Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nguyen J; Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Devlin S; Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lendvai N; Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weltz J; Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ayorinde T; Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chung DJ; Adult Bone Marrow Transplant Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lesokhin AM; Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kewalramani T; Department of Hematology/Oncology, Lahey Hospital & Medical Center, Burlington, MA, USA.
Korde N; Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mailankody S; Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Landgren O; Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Giralt S; Adult Bone Marrow Transplant Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Comenzo RL; Hematology/Oncology Service, Department of Medicine, Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA, USA.
Hassoun H; Myeloma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Sep; Vol. 63 (9), pp. 2126-2135. Date of Electronic Publication: 2022 Jun 01.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/methods
Multiple Myeloma*/drug therapy
Multiple Myeloma*/therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Humans ; Lenalidomide/therapeutic use ; Prospective Studies ; Stem Cell Transplantation ; Transplantation, Autologous
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.
Autorzy:
Taenaka R; Department of Hematology and Oncology, JCHO Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan. .; Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine, 3-1-1 Maidashi, Higashi-ku, Fukuoka City, Fukuoka, Japan. .
Shimokawa S; Department of Ophthalmology, JCHO Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan.
Katayama A; Department of Dermatology, JCHO Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan.
Nagao T; Department of Endocrinology and Metabolism, JCHO Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan.
Obara T; Department of Hematology and Oncology, JCHO Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan.
Nishimura N; Department of Pharmacy, JCHO Kyushu Hospital, 1-8-1, Kishinoura, Yahatanisi-ku, Kitakyushu, Fukuoka, Japan.
Tsujimoto A; Department of Neurology, JCHO Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan.
Kohno K; Department of Hematology and Oncology, JCHO Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan.
Aoki K; Department of Hematology and Oncology, JCHO Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan.
Ogawa R; Department of Hematology and Oncology, JCHO Kyushu Hospital, 1-8-1 Kishinoura, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan.
Pokaż więcej
Źródło:
Journal of medical case reports [J Med Case Rep] 2022 Aug 18; Vol. 16 (1), pp. 311. Date of Electronic Publication: 2022 Aug 18.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Endocrine System Diseases*
Hematopoietic Stem Cell Transplantation*
Heterocyclic Compounds*
Polyneuropathies*/drug therapy
Adult ; Antibodies, Monoclonal ; Dexamethasone/therapeutic use ; Female ; Filgrastim ; Hematopoietic Stem Cell Mobilization ; Humans ; Lenalidomide ; Transplantation, Autologous
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States.
Autorzy:
Medhekar R; Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA, 19044, USA. .
Ran T; Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA, 19044, USA.
Fu AZ; Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA, 19044, USA.; Georgetown University Medical Center, 37th and O Street, NW, Washington, DC, 20057, USA.
Patel S; Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA, 19044, USA.
Kaila S; Janssen Scientific Affairs, LLC, 800 Ridgeview Drive, Horsham, PA, 19044, USA.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Aug 18; Vol. 22 (1), pp. 901. Date of Electronic Publication: 2022 Aug 18.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Multiple Myeloma*/therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib ; Dexamethasone ; Disease Progression ; Humans ; Lenalidomide/therapeutic use ; Retrospective Studies ; Treatment Outcome ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Post-transplant strategies to improve relapse-free survival in childhood leukemia: Whole blood donor lymphocyte infusions and lenalidomide for inducing graft-versus-leukemia effect.
Autorzy:
Chandar R; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Hospitals, Chennai, India.
Meena S; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Hospitals, Chennai, India.
Varla H; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Hospitals, Chennai, India.
Ramakrishnan B; Department of Biostatistics, Apollo Hospitals, Chennai, India.
Vellaichamy Swaminathan V; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Hospitals, Chennai, India.
Uppuluri R; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Hospitals, Chennai, India.
Raj R; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Hospitals, Chennai, India.
Pokaż więcej
Źródło:
Pediatric transplantation [Pediatr Transplant] 2022 Aug; Vol. 26 (5), pp. e14293. Date of Electronic Publication: 2022 Apr 18.
Typ publikacji:
Journal Article
MeSH Terms:
Graft vs Host Disease*/prevention & control
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*
Blood Donors ; Child ; Humans ; Lenalidomide/therapeutic use ; Lymphocytes ; Recurrence ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Carfilzomib 56 mg/m twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison.
Autorzy:
Weisel K; Department of Oncology and Hematology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
Nooka AK; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Terpos E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Spencer A; Australian Centre for Blood Diseases, Monash University, Malignant Haematology & Stem Cell Transplantation, Alfred Hospital and Department of Clinical Haematology, Monash University, Melbourne, Australia.
Goldschmidt H; Internal Medicine V and National Center of Tumor Diseases, University Clinic Heidelberg, Heidelberg, Germany.
Dirnberger F; Global Value and Access, Amgen GmbH, Munich, Germany.
DeCosta L; Global Biostatistical Science, Amgen Ltd., Uxbridge, UK.
Yusuf A; Global Medical Affairs, Amgen Inc., Thousand Oaks, CA, USA.
Kumar S; Department of Internal Medicine, Division of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Aug; Vol. 63 (8), pp. 1887-1896. Date of Electronic Publication: 2022 Mar 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Multiple Myeloma*/drug therapy
Antibodies, Monoclonal ; Bortezomib/therapeutic use ; Dexamethasone/therapeutic use ; Humans ; Lenalidomide/therapeutic use ; Neoplasm Recurrence, Local/drug therapy ; Oligopeptides
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Investigation of the Chemical Stability of Lenalidomide in Methanol/Ethanol Solvents Using RP-HPLC-UV and LC-MS.
Autorzy:
Alzweiri, Muhammed
Aqel, Qusai
Sweidan, Kamal
Pokaż więcej
Alternatywny tytuł:
التحقق من االستقرار الكيميائي للليناليدوميد في مذيبات الميثانول / اإليثانول باستخدام الطور العكسي للكروماتوغرافيه والكروماتغرافيه السائلة مع مطياف الكتلة.
Źródło:
Jordan Journal of Pharmaceutical Sciences. Sep2022, Vol. 15 Issue 3, p305-314. 10p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 41-60 z 6880

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies